Outcomes in HIV-infected patients admitted due to pandemic influenza.
Identifieur interne : 000310 ( Main/Exploration ); précédent : 000309; suivant : 000311Outcomes in HIV-infected patients admitted due to pandemic influenza.
Auteurs : José L Pez-Aldeguer [Espagne] ; José A. Iribarren ; Eulalia Valencia ; Elena Barquilla ; Hernando Knobel ; Jesús Santos ; Fernando LozanoSource :
- Enfermedades infecciosas y microbiologia clinica [ 1578-1852 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Agents antiVIH (usage thérapeutique), Antiviraux (usage thérapeutique), Comorbidité (MeSH), Durée du séjour (MeSH), Espagne (épidémiologie), Femelle (MeSH), Fumer (épidémiologie), Grippe humaine (traitement médicamenteux), Grippe humaine (épidémiologie), Humains (MeSH), Infections à VIH (traitement médicamenteux), Infections à VIH (épidémiologie), Maladies de l'appareil respiratoire (épidémiologie), Mortalité hospitalière (MeSH), Mâle (MeSH), Numération des lymphocytes CD4 (MeSH), Obésité (épidémiologie), Oséltamivir (usage thérapeutique), Pandémies (MeSH), Patients hospitalisés (statistiques et données numériques), Résultat thérapeutique (MeSH), Sepsie (épidémiologie), Sous-type H1N1 du virus de la grippe A (MeSH), Unités de soins intensifs (statistiques et données numériques), Vaccination (statistiques et données numériques), Vaccins antigrippaux (MeSH), Études de cohortes (MeSH), Évaluation des symptômes (MeSH).
- MESH :
- statistiques et données numériques : Patients hospitalisés, Unités de soins intensifs, Vaccination.
- traitement médicamenteux : Grippe humaine, Infections à VIH.
- usage thérapeutique : Agents antiVIH, Antiviraux, Oséltamivir.
- épidémiologie : Espagne, Fumer, Grippe humaine, Infections à VIH, Maladies de l'appareil respiratoire, Obésité, Sepsie.
- Adulte, Adulte d'âge moyen, Comorbidité, Durée du séjour, Femelle, Humains, Mortalité hospitalière, Mâle, Numération des lymphocytes CD4, Pandémies, Résultat thérapeutique, Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux, Études de cohortes, Évaluation des symptômes.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adult (MeSH), Anti-HIV Agents (therapeutic use), Antiviral Agents (therapeutic use), CD4 Lymphocyte Count (MeSH), Cohort Studies (MeSH), Comorbidity (MeSH), Female (MeSH), HIV Infections (drug therapy), HIV Infections (epidemiology), Hospital Mortality (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (MeSH), Influenza Vaccines (MeSH), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Inpatients (statistics & numerical data), Intensive Care Units (statistics & numerical data), Length of Stay (MeSH), Male (MeSH), Middle Aged (MeSH), Obesity (epidemiology), Oseltamivir (therapeutic use), Pandemics (MeSH), Respiratory Tract Diseases (epidemiology), Sepsis (epidemiology), Smoking (epidemiology), Spain (epidemiology), Symptom Assessment (MeSH), Treatment Outcome (MeSH), Vaccination (statistics & numerical data).
- MESH :
- chemical , therapeutic use : Anti-HIV Agents, Antiviral Agents, Oseltamivir.
- geographic , epidemiology : Spain.
- drug therapy : HIV Infections, Influenza, Human.
- epidemiology : HIV Infections, Influenza, Human, Obesity, Respiratory Tract Diseases, Sepsis, Smoking.
- statistics & numerical data : Inpatients, Intensive Care Units, Vaccination.
- Adult, CD4 Lymphocyte Count, Cohort Studies, Comorbidity, Female, Hospital Mortality, Humans, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Length of Stay, Male, Middle Aged, Pandemics, Symptom Assessment, Treatment Outcome.
Abstract
PURPOSE
To determine the clinical, epidemiological and prognostic factors of HIV-infected patients with influenza A H1N1 admitted to hospital.
METHODS
The study population was HIV infected patients with confirmed influenza infection admitted to hospital in a multicenter cohort. We analyzed demographic data, comorbid conditions, severe events (bronchopneumonia, respiratory insufficiency, respiratory distress, sepsis, admission to intensive care unit, death) and outcome. Data were analyzed using descriptive statistics. Proportions were compared using the χ(2) test or Fisher exact test, when applicable. Quantitative variables were compared using the Student t test or Mann-Whitney test. Prognostic impact was analyzed using logistic regression.
RESULTS
A total of 43 patients, of whom 62.8% were male, were included from 22 hospitals. The mean age was 43.3 years (interquartile range [IQR], 38.4-48.4). HIV was diagnosed for a mean of 14.5 years (IQR, 8.4-20.3). CD4 lymphocyte was <200 cells/μL in 38%; 85.7% were on antiretroviral therapy, and 66.7% virologically suppressed. Comorbid conditions were hepatitis B or C (74.4%), smoking (67.4%), chronic obstructive pulmonary disease (30.2%), asthma (14%), and obesity (8.6%). Seven patients had received seasonal influenza vaccination, and 2 the H1N1 vaccine. Cough (100%), fever (93%), gastrointestinal disorders (27.9%) or general--myalgia, general malaise--(67.4%) were the presenting symptoms. These were severe in 24 (55.8%) with 7 (16.3%) requiring intensive care. Two patients died. A lower CD4 lymphocyte count was associated with bacterial infection (P=.063) and longer hospital stay (P=.007). Early oseltamivir reduced severe cases (OR, 4.5; 1.1-18.3; P=.035).
CONCLUSIONS
HIV-infected patients admitted to hospital due to influenza A H1N1 had severe morbidity. Low CD4 lymphocytes correlated with longer hospitalization and bacterial infections. Early oseltamivir treatment reduced severe symptoms.
DOI: 10.1016/j.eimc.2012.02.007
PubMed: 22459686
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes in HIV-infected patients admitted due to pandemic influenza.</title><author><name sortKey="L Pez Aldeguer, Jose" sort="L Pez Aldeguer, Jose" uniqKey="L Pez Aldeguer J" first="José" last="L Pez-Aldeguer">José L Pez-Aldeguer</name><affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital La Fe, Valencia, Spain. lopez_jos@gva.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital La Fe, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Iribarren, Jose A" sort="Iribarren, Jose A" uniqKey="Iribarren J" first="José A" last="Iribarren">José A. Iribarren</name></author><author><name sortKey="Valencia, Eulalia" sort="Valencia, Eulalia" uniqKey="Valencia E" first="Eulalia" last="Valencia">Eulalia Valencia</name></author><author><name sortKey="Barquilla, Elena" sort="Barquilla, Elena" uniqKey="Barquilla E" first="Elena" last="Barquilla">Elena Barquilla</name></author><author><name sortKey="Knobel, Hernando" sort="Knobel, Hernando" uniqKey="Knobel H" first="Hernando" last="Knobel">Hernando Knobel</name></author><author><name sortKey="Santos, Jesus" sort="Santos, Jesus" uniqKey="Santos J" first="Jesús" last="Santos">Jesús Santos</name></author><author><name sortKey="Lozano, Fernando" sort="Lozano, Fernando" uniqKey="Lozano F" first="Fernando" last="Lozano">Fernando Lozano</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22459686</idno><idno type="pmid">22459686</idno><idno type="doi">10.1016/j.eimc.2012.02.007</idno><idno type="wicri:Area/Main/Corpus">00307</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00307</idno><idno type="wicri:Area/Main/Curation">000307</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000307</idno><idno type="wicri:Area/Main/Exploration">000307</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Outcomes in HIV-infected patients admitted due to pandemic influenza.</title><author><name sortKey="L Pez Aldeguer, Jose" sort="L Pez Aldeguer, Jose" uniqKey="L Pez Aldeguer J" first="José" last="L Pez-Aldeguer">José L Pez-Aldeguer</name><affiliation wicri:level="1"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital La Fe, Valencia, Spain. lopez_jos@gva.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital La Fe, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Iribarren, Jose A" sort="Iribarren, Jose A" uniqKey="Iribarren J" first="José A" last="Iribarren">José A. Iribarren</name></author><author><name sortKey="Valencia, Eulalia" sort="Valencia, Eulalia" uniqKey="Valencia E" first="Eulalia" last="Valencia">Eulalia Valencia</name></author><author><name sortKey="Barquilla, Elena" sort="Barquilla, Elena" uniqKey="Barquilla E" first="Elena" last="Barquilla">Elena Barquilla</name></author><author><name sortKey="Knobel, Hernando" sort="Knobel, Hernando" uniqKey="Knobel H" first="Hernando" last="Knobel">Hernando Knobel</name></author><author><name sortKey="Santos, Jesus" sort="Santos, Jesus" uniqKey="Santos J" first="Jesús" last="Santos">Jesús Santos</name></author><author><name sortKey="Lozano, Fernando" sort="Lozano, Fernando" uniqKey="Lozano F" first="Fernando" last="Lozano">Fernando Lozano</name></author></analytic><series><title level="j">Enfermedades infecciosas y microbiologia clinica</title><idno type="eISSN">1578-1852</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>CD4 Lymphocyte Count (MeSH)</term><term>Cohort Studies (MeSH)</term><term>Comorbidity (MeSH)</term><term>Female (MeSH)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>Hospital Mortality (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (MeSH)</term><term>Influenza Vaccines (MeSH)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Inpatients (statistics & numerical data)</term><term>Intensive Care Units (statistics & numerical data)</term><term>Length of Stay (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Obesity (epidemiology)</term><term>Oseltamivir (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Respiratory Tract Diseases (epidemiology)</term><term>Sepsis (epidemiology)</term><term>Smoking (epidemiology)</term><term>Spain (epidemiology)</term><term>Symptom Assessment (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Vaccination (statistics & numerical data)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Agents antiVIH (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Comorbidité (MeSH)</term><term>Durée du séjour (MeSH)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Fumer (épidémiologie)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (épidémiologie)</term><term>Maladies de l'appareil respiratoire (épidémiologie)</term><term>Mortalité hospitalière (MeSH)</term><term>Mâle (MeSH)</term><term>Numération des lymphocytes CD4 (MeSH)</term><term>Obésité (épidémiologie)</term><term>Oséltamivir (usage thérapeutique)</term><term>Pandémies (MeSH)</term><term>Patients hospitalisés (statistiques et données numériques)</term><term>Résultat thérapeutique (MeSH)</term><term>Sepsie (épidémiologie)</term><term>Sous-type H1N1 du virus de la grippe A (MeSH)</term><term>Unités de soins intensifs (statistiques et données numériques)</term><term>Vaccination (statistiques et données numériques)</term><term>Vaccins antigrippaux (MeSH)</term><term>Études de cohortes (MeSH)</term><term>Évaluation des symptômes (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Antiviral Agents</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term><term>Influenza, Human</term><term>Obesity</term><term>Respiratory Tract Diseases</term><term>Sepsis</term><term>Smoking</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Inpatients</term><term>Intensive Care Units</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Patients hospitalisés</term><term>Unités de soins intensifs</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Fumer</term><term>Grippe humaine</term><term>Infections à VIH</term><term>Maladies de l'appareil respiratoire</term><term>Obésité</term><term>Sepsie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Cohort Studies</term><term>Comorbidity</term><term>Female</term><term>Hospital Mortality</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term><term>Length of Stay</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Symptom Assessment</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Comorbidité</term><term>Durée du séjour</term><term>Femelle</term><term>Humains</term><term>Mortalité hospitalière</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Pandémies</term><term>Résultat thérapeutique</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Études de cohortes</term><term>Évaluation des symptômes</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b></p><p>To determine the clinical, epidemiological and prognostic factors of HIV-infected patients with influenza A H1N1 admitted to hospital.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>The study population was HIV infected patients with confirmed influenza infection admitted to hospital in a multicenter cohort. We analyzed demographic data, comorbid conditions, severe events (bronchopneumonia, respiratory insufficiency, respiratory distress, sepsis, admission to intensive care unit, death) and outcome. Data were analyzed using descriptive statistics. Proportions were compared using the χ(2) test or Fisher exact test, when applicable. Quantitative variables were compared using the Student t test or Mann-Whitney test. Prognostic impact was analyzed using logistic regression.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 43 patients, of whom 62.8% were male, were included from 22 hospitals. The mean age was 43.3 years (interquartile range [IQR], 38.4-48.4). HIV was diagnosed for a mean of 14.5 years (IQR, 8.4-20.3). CD4 lymphocyte was <200 cells/μL in 38%; 85.7% were on antiretroviral therapy, and 66.7% virologically suppressed. Comorbid conditions were hepatitis B or C (74.4%), smoking (67.4%), chronic obstructive pulmonary disease (30.2%), asthma (14%), and obesity (8.6%). Seven patients had received seasonal influenza vaccination, and 2 the H1N1 vaccine. Cough (100%), fever (93%), gastrointestinal disorders (27.9%) or general--myalgia, general malaise--(67.4%) were the presenting symptoms. These were severe in 24 (55.8%) with 7 (16.3%) requiring intensive care. Two patients died. A lower CD4 lymphocyte count was associated with bacterial infection (P=.063) and longer hospital stay (P=.007). Early oseltamivir reduced severe cases (OR, 4.5; 1.1-18.3; P=.035).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>HIV-infected patients admitted to hospital due to influenza A H1N1 had severe morbidity. Low CD4 lymphocytes correlated with longer hospitalization and bacterial infections. Early oseltamivir treatment reduced severe symptoms.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22459686</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1852</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Enfermedades infecciosas y microbiologia clinica</Title><ISOAbbreviation>Enferm. Infecc. Microbiol. Clin.</ISOAbbreviation></Journal><ArticleTitle>Outcomes in HIV-infected patients admitted due to pandemic influenza.</ArticleTitle><Pagination><MedlinePgn>608-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eimc.2012.02.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0213-005X(12)00113-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To determine the clinical, epidemiological and prognostic factors of HIV-infected patients with influenza A H1N1 admitted to hospital.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study population was HIV infected patients with confirmed influenza infection admitted to hospital in a multicenter cohort. We analyzed demographic data, comorbid conditions, severe events (bronchopneumonia, respiratory insufficiency, respiratory distress, sepsis, admission to intensive care unit, death) and outcome. Data were analyzed using descriptive statistics. Proportions were compared using the χ(2) test or Fisher exact test, when applicable. Quantitative variables were compared using the Student t test or Mann-Whitney test. Prognostic impact was analyzed using logistic regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 43 patients, of whom 62.8% were male, were included from 22 hospitals. The mean age was 43.3 years (interquartile range [IQR], 38.4-48.4). HIV was diagnosed for a mean of 14.5 years (IQR, 8.4-20.3). CD4 lymphocyte was <200 cells/μL in 38%; 85.7% were on antiretroviral therapy, and 66.7% virologically suppressed. Comorbid conditions were hepatitis B or C (74.4%), smoking (67.4%), chronic obstructive pulmonary disease (30.2%), asthma (14%), and obesity (8.6%). Seven patients had received seasonal influenza vaccination, and 2 the H1N1 vaccine. Cough (100%), fever (93%), gastrointestinal disorders (27.9%) or general--myalgia, general malaise--(67.4%) were the presenting symptoms. These were severe in 24 (55.8%) with 7 (16.3%) requiring intensive care. Two patients died. A lower CD4 lymphocyte count was associated with bacterial infection (P=.063) and longer hospital stay (P=.007). Early oseltamivir reduced severe cases (OR, 4.5; 1.1-18.3; P=.035).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HIV-infected patients admitted to hospital due to influenza A H1N1 had severe morbidity. Low CD4 lymphocytes correlated with longer hospitalization and bacterial infections. Early oseltamivir treatment reduced severe symptoms.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier España, S.L. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>López-Aldeguer</LastName><ForeName>José</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidad de Enfermedades Infecciosas, Hospital La Fe, Valencia, Spain. lopez_jos@gva.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iribarren</LastName><ForeName>José A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Valencia</LastName><ForeName>Eulalia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Barquilla</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Knobel</LastName><ForeName>Hernando</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Jesús</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><CollectiveName>GESIDA 6409 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Enferm Infecc Microbiol Clin</MedlineTA><NlmUniqueID>9104081</NlmUniqueID><ISSNLinking>0213-005X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012140" MajorTopicYN="N">Respiratory Tract Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Valencia Ortega</LastName><ForeName>Eulalia</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>López Aldeguer</LastName><ForeName>José</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oteo</LastName><ForeName>José Antonio</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanco</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curran Fabregas</LastName><ForeName>Adria</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iribarren</LastName><ForeName>José Antonio</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jesús Bustinduy</LastName><ForeName>María</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knobel</LastName><ForeName>Hernando</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portu Zapirain</LastName><ForeName>Joseba</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Force Sanmartín</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sola Boneta</LastName><ForeName>Julio</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutierrez Rodero</LastName><ForeName>Félix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrer Ribera</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Podzamzer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amador Prous</LastName><ForeName>Concepción</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>González de Suso</LastName><ForeName>Miguel Torralba</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramírez Montesinos</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cervero Jiménez</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lozano de León</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Estrada Pérez</LastName><ForeName>Vicente</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gómez Sirvent</LastName><ForeName>Juan Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mora Rillo</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alonso-Vega</LastName><ForeName>Gabriel Gaspar</ForeName><Initials>GG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santos</LastName><ForeName>Jesús</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barquilla</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>01</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>02</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22459686</ArticleId><ArticleId IdType="pii">S0213-005X(12)00113-9</ArticleId><ArticleId IdType="doi">10.1016/j.eimc.2012.02.007</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><noCountry><name sortKey="Barquilla, Elena" sort="Barquilla, Elena" uniqKey="Barquilla E" first="Elena" last="Barquilla">Elena Barquilla</name><name sortKey="Iribarren, Jose A" sort="Iribarren, Jose A" uniqKey="Iribarren J" first="José A" last="Iribarren">José A. Iribarren</name><name sortKey="Knobel, Hernando" sort="Knobel, Hernando" uniqKey="Knobel H" first="Hernando" last="Knobel">Hernando Knobel</name><name sortKey="Lozano, Fernando" sort="Lozano, Fernando" uniqKey="Lozano F" first="Fernando" last="Lozano">Fernando Lozano</name><name sortKey="Santos, Jesus" sort="Santos, Jesus" uniqKey="Santos J" first="Jesús" last="Santos">Jesús Santos</name><name sortKey="Valencia, Eulalia" sort="Valencia, Eulalia" uniqKey="Valencia E" first="Eulalia" last="Valencia">Eulalia Valencia</name></noCountry><country name="Espagne"><noRegion><name sortKey="L Pez Aldeguer, Jose" sort="L Pez Aldeguer, Jose" uniqKey="L Pez Aldeguer J" first="José" last="L Pez-Aldeguer">José L Pez-Aldeguer</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000310 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000310 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22459686
|texte= Outcomes in HIV-infected patients admitted due to pandemic influenza.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22459686" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |